Medicamen Biotech Limited Financial Ratios
MEDICAMEQ · Healthcare · Current price ₹286.5
P/E ratio
39.7x
P/B ratio
1.5x
ROE
3.5%
ROCE
4.8%
Debt / Equity
0.17
Dividend yield
0.3%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 39.7x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 1.5x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 3.5% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 4.8% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.17 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Medicamen Biotech Limited's latest numbers.
Medicamen Biotech Limited profitability
Medicamen Biotech Limited generates a return on equity of 3.5% and a return on capital employed of 4.8%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.17 and a P/E of 39.7x, Medicamen Biotech Limited is conservatively financed. Our overall business-quality score for the company is 3.0 / 10.
Understand the ratios
More on Medicamen Biotech Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.